Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Ariceum Therapeutics GmbH
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Signed Informed Consent Form and willing to comply with all study procedures.
Participants with ES-SCLC (defined as Stage IV per NCCN guidelines Version 1.2024) or recurrent locally advanced or metastatic MCC (per NCCN guidelines Version 1.2024) documented by histology or cytology.
Participants eligible to receive immune checkpoint inhibitor (CPI) monotherapy at the start of treatment with 225Ac-SSO110 or patients already on CPI monotherapy for 7 weeks.
ECOG performance status of 0 or 1. Life expectancy of at least 6 months.
Positive 68Ga-SSO120 scan (Investigator-assessed) during screening.
You may not be if
Participants with unstable spinal cord compression.
Any previous systemic radioligand therapy or extensive radiotherapy.
Participants receiving or planned to receive consolidative chest radiation.
History of primary immunodeficiency, transplantation or CAR-T cell therapy.
Major surgical procedure except diagnostic biopsy within 28 days prior to enrolment or scheduled to have major surgery during the study.
Inadequate organ or marrow function.
Clareo Health | Study of 225Ac-SS0110 in Subjects With ES-SCLC or MCC (SANTANA-225 )
